Candidate List of yoUr Biomarker (CLUB): A Web-based Platform to Aid Cancer Biomarker Research by Lee, Bernett T.K. et al.
Biomarker Insights 2008:3 65–71 65
SOFTWARE OR DATABASE REVIEW
Correspondence: N. Leigh Anderson, The Plasma Proteome Institute, P.O. Box 53450, Washington DC, 
20009-3450, USA; Tel: (301) 728-1451; Fax: (202) 234-9175; Email: leighanderson@plasmaproteome.org
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Candidate List of yoUr Biomarker (CLUB): A Web-based 
Platform to Aid Cancer Biomarker Research
Bernett T.K. Lee
1, Lailing Liew
1, Jiahao Lim
1, Jonathan K.L. Tan
1, Tze Chuen Lee
1, 
Pardha S. Veladandi
1, Yun Ping Lim
1, Hao Han
1, Gunaretnam Rajagopal
1 and 
N. Leigh Anderson
2
1Bioinformatics Institute, 30 Biopolis Street, #07-01, Singapore 138671. 
2The Plasma Proteome 
Insitute, P.O. Box: 53450, Washington DC, 20009-3450, U.S.A.
Abstract: CLUB (“Candidate List of yoUr Biomarkers”) is a freely available, web-based resource designed to support 
Cancer biomarker research. It is targeted to provide a comprehensive list of candidate biomarkers for various cancers that 
have been reported by the research community. CLUB provides tools for comparison of marker candidates from different 
experimental platforms, with the ability to ﬁ  lter, search, query and explore, molecular interaction networks associated with 
cancer biomarkers from the published literature and from data uploaded by the community. This complex and ambitious 
project is implemented in phases. As a ﬁ  rst step, we have compiled from the literature an initial set of differentially expressed 
human candidate cancer biomarkers. Each candidate is annotated with information from publicly available databases such 
as Gene Ontology, Swiss-Prot database, National Center for Biotechnology Information’s reference sequences, Biomo-
lecular Interaction Network Database and IntAct interaction. The user has the option to maintain private lists of biomarker 
candidates or share and export these for use by the community. Furthermore, users may customize and combine commonly 
used sets of selection procedures and apply them as a stored workﬂ  ow using selected candidate lists. To enable an assess-
ment by the user before taking a candidate biomarker to the experimental validation stage, the platform contains the func-
tionality to identify pathways associated with cancer risk, staging, prognosis, outcome in cancer and other clinically 
associated phenotypes. The system is available at http://club.bii.a-star.edu.sg.
Introduction
Biomarkers are molecular signatures that can serve as early warning signs of disease, measure disease 
progression or monitor the physiological effects of therapeutic interventions in the treatment of disease. 
Biomarker discovery is often carried out by comparing normal and disease states by differential gene/
protein expression and changes in metabolic proﬁ  les. The hope of ﬁ  nding new biomarkers for assessing 
cancer risk, detecting cancer at an early stage, subtyping tumors, selecting optimal therapies, and 
monitoring therapeutic response is the motivation behind substantial current investments in biomarker 
research. Success in this effort can yield revolutionary improvements in the management of cancer. 
However, despite considerable public and private resources invested in biomarker discovery over the 
past twenty years, and a plethora of candidate biomarkers (Pritzker, 2002), the results in terms of 
clinical impact have been disappointing. To date, very few biomarkers have been approved by the Food 
and Drug Administration (FDA) for use in cancer diagnosis and therapy (Anderson and Anderson, 
2002). While technical limitations in detecting biomarkers (Diamandis, 2004) represents one reason 
for this shortfall, poor study design, population heterogeneity and methodological weaknesses in data 
collection and analysis (Baggerly et al. 2005; Ransohoff, 2005; Zhang and Chan, 2005) have led to the 
reporting of numerous candidate biomarker sets for a given disease that show little or no overlap between 
studies. This lack of replication has undermined conﬁ  dence that truly disease-associated clinically use-
ful biomarkers can be found.
While much progress is being made around the world, veriﬁ  cation and validation of putative bio-
markers is difﬁ  cult even if the shortcomings listed above can be overcome. In particular, given limited 
capacity to undertake candidate veriﬁ  cation studies, any effective means that prioritize candidate bio-
markers based on biological insight would be very useful (Aebersold et al. 2005). Given that there is 
already a depth of published knowledge from various studies (not all of which are of the same quality) 
it would be good if there existed a central repository bringing together the wealth of information from 66
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the literature for the discovery of truly clinically 
useful biomarkers. It would also serve as a 
community-wide platform where biomarker groups 
could share and compare protocols and data. Such 
a database should ideally be platform neutral so 
that researchers working on proteomics, microar-
ray or other expression-based experiments can use 
the system to upload, ﬁ  lter, share, compare and 
analyze the candidate biomarkers.
To this end, given that effective therapies are 
targeting speciﬁ  c cancer pathways, we have devel-
oped and deployed CLUB (Candidate List of yoUr 
Biomarkers), which enables users to discover and 
document such pathways related to a particular 
disease subtype (Aebersold et al. 2005). While our 
focus is on cancer, its basic framework can be eas-
ily modiﬁ  ed for other diseases. Part of the data 
within CLUB is derived from peer reviewed jour-
nals and is updated on a regular basis by an expe-
rienced team of curators. The 1261 candidate 
cancer biomarkers compiled by Polanski and 
Anderson (Polanski and Anderson, 2006), for 
example and other data can now be found in the 
system and is available for users to conduct mean-
ingful comparisons, gene enrichments, stratify and 
analyze biomarker interaction networks to come 
up with interesting hypothesis. The molecular 
interaction features within CLUB also provide 
users with a means to understand the biological 
basis of why certain biomarkers work. Along with 
information from the literature and the pathway 
interaction tool, potentially important features of 
candidate biomarkers related to drug targets, treat-
ment outcome and response to therapy may be 
discovered.
The utility of CLUB differs from earlier bio-
marker databases. The Biomarker Database 
(BMDB) by Feng and coworkers (Feng et al. 2005) 
caters only to microarray analysis, has limited 
curated information from the literature, and does 
not obtain manually curated interaction data for 
pathway related analysis. The BioMarker Database 
(BioMarker DB) developed by Jubilant Biosystem 
Ltd. is a repository for curated biomarkers. The 
Biomarker Database funded by The Korea National 
Institute of Health (http://biomarker.cdc.go.kr:8080/
About/AboutBD_en.jsp?m=BD) focused on 
depositing infectious disease related biomarker and 
UniPep (Zhang et al. 2006) is a resource for N-
linked glycosites from human serum biomarker 
discovery. While these tools are useful resources, 
CLUB is targeted instead towards community-wide 
participation in the aggregation, comparison, 
annotation and use of multiple biomarker candidate 
lists. With the capability to make comparisons 
between gene lists and discover biologically mean-
ingful interactions, biomarkers that enable early 
diagnosis, monitor therapeutic responses, estimate 
disease prognosis and predict chemotherapeutic 
responses and resistance could be discovered using 
the system. As CLUB focuses on the ability to 
make comparisons between gene lists, complex 
statistical analysis tools have not been implement-
ed and users are advised to download the data for 
use in a separate statistical package. As CLUB 
continues to evolve with more user feedback, we 
envision that its user-friendly community—wide 
access approach will enable systemic collection of 
data sets from the community and facilitate the 
selection of candidate biomarkers for validation. 
By this evolving process it will help to close the 
gap between basic research and FDA-approved 
clinically useful biomarkers.
Results
CLUB was designed to be platform neutral and 
thus is available to all as a web service. Users can 
access the service via a standard web browser, with 
some of the visualization components requiring 
the use of a Java plugin, which is available for most 
platforms (Fig. 1). A simple one-time registration 
is required to gain secure access to privately saved 
data. In order to initiate the community contribu-
tion process, we have embarked on a curation 
exercise to populate CLUB with an initial cancer-
related dataset from publications using high-
throughput technologies, especially those 
employing microarrays and mass spectrometry. As 
of June 2007, details of 55 lists of various cancer-
types from 41 papers containing 4326 distinct 
International Protein Index (IPI) protein records 
and 3096 distinct Entrez Gene records have been 
curated and are available in CLUB’s public data 
section (Fig. 2). We are also working with Inter-
national Cancer Biomarker Consortium (ICBC) to 
facilitate use of CLUB by the cancer biomarker 
community.
In CLUB, every biomarker candidate is assigned 
a corresponding NCBI Entrez Gene ID and/or IPI 
identiﬁ  er, regardless of the accession number sys-
tem in which identiﬁ  cations are originally reported. 
This consistent identiﬁ  er forms the basis for com-
paring stored processed candidate biomarkers 67
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Figure 1. Sample screenshots from CLUB where user can conduct comparisons and various analyses on a list of candidate bio-
markers.
(A) Logo of CLUB. (B) The Create List of Candidate Biomarker page. User may input biomarker based on a template or upload them directly 
from ﬁ  le with sixteen different recognizable identiﬁ  ers. (C) The View Candidate List page where information about individual candidate 
biomarkers can be found. (D) Candidate Manipulations page where various analyses can be conducted. (E) Workﬂ  ow page where user may 
customize and combine commonly used sets of operations to run them in a series.
across all the different technology platforms, and 
overcomes a major barrier in comparing published 
biomarkers sets identiﬁ  ed in different accession 
systems. Metadata of the candidate biomarker such 
as fold change, type of deregulation, and informa-
tion about the candidate list such as sample type, 
experimental setups, category of candidate bio-
marker, stage of cancer, available publications etc. 
may also be entered into the system. These meta-
data also serves as a means to compare, search and 
ﬁ  lter biomarker candidates.
Users may upload biomarker candidates and 
save them as a list of candidates with sixteen com-
monly used identiﬁ  ers (Fig. 1B). The original 
uploaded identiﬁ  ers will be mapped to a corre-
sponding Entrez Gene ID and an IPI identiﬁ  er. As 
heterogeneous data from various experimental 
platforms are compared in the system, details from 
the unprocessed raw data were omitted from the 
ﬁ  le upload section. Users may also include detailed 
unprocessed data and/or PubMed references via 
hyperlinks (Fig. 1C). Each individual candidate is 
also annotated with information from Swiss-Prot 
(Bairoch and Apweiler, 1997), Gene Ontology 
(Ashburner et al. 2000) and GenMAPP (Dahlquist 
et al. 2002). Lists of biomarker candidates (usually 
tied to a speciﬁ  c experiment or a group of candi-
dates) and individual biomarker candidates may 68
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CLUB General Statistics
Total number of Candidate Lists          55
Candidate Lists from Publications          41
Candidate Lists from Unpublished Data     1
Unique IPI Protein Records                     4326
Unique Entrez Gene Records                    3096
Breakdown of Candidate Lists by Disease
Disease Publications (Pubmed) Candidate Lists
Bladder Cancer
Bone Marrow
Breast Cancer
Colon Cancer
Colorectal Cancer
Follicular lymphoma
Gastric Cancer
Hepatocellular Cancer
Head neck thyroid Cancer
Nasopharyngeal Cancer
Neuroblastoma
Buccal Squamous Cell Cancer
Ovarian Cancer
Pancreatic Cancer
Pineal Parenchymal Tumors
Prostate Cancer
Renal Cancer
Thyroid Cancer
Others
Total
1
1
5
1
4
2
3
4
2
1
1
1
4
1
2
3
1
2
2
41
1
1
6
1
4
2
4
4
4
1
2
1
8
1
5
3
1
3
3
55
Figure 2. General Statistics of the number of candidate gene and protein biomarkers in CLUB.
Details of 55 candidate lists of various cancer-types containing 4326 distinct International Protein Index protein records and 3096 distinct 
Entrez Gene records have been curated in CLUB.
be searched, browsed, shared with fellow CLUB 
users, saved, exported (in Microsoft Excel format) 
and managed in folders. Users may also have an 
overview of the detailed information of their 
selected list of biomarker candidates. Information 
such as the type of disease, stage of the cancer 
samples, purpose and design of the experiments 
and other details about the biomarker candidates 
may be displayed at the overview page.
Recent therapeutic strategies are evolving to 
target cancer specific signal transduction and 
metabolic pathways and it is becoming important 
to document these pathways as powerful tools in 
cancer management (Aebersold et al. 2005; 
Gulmann et al. 2006). Hence, pathway analysis 
and pathway discovery of cancer subtypes are 
becoming increasingly important for the under-
standing of the pathophysiology of neoplasia and 
anticancer drug discovery (Cho, 2007; Efroni et al. 
2007). CLUB facilitates analysis of this nature by 
incorporating manually-curated interaction data 
from BIND (Bader et al. 2003) and IntAct interac-
tion database (Kerrien et al. 2007). Users may use 
an “interaction operator” to ﬁ  nd how a list of can-
didate biomarkers interacts with another list (say 
apoptosis related proteins, oncogenes or tumor 
suppressors). Links to the references that describes 
the interactions found in the network generated are 69
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available. The interaction visualization tool may 
be used to see interacting or regulating genes or 
proteins within a given list.
A range of functionalities can be used to per-
form analysis on a candidate list or between can-
didate lists (Fig. 1D). Biomarker candidates may 
be f iltered by protein molecular weight, isoelectric 
point, gene ontology, presence in cancer related 
pathways, or according to whether they are clas-
siﬁ  ed or annotated by Gene Ontology and Swiss-
Prot as a secreted protein. User may also use 
boolean set operations to compare candidate bio-
markers from any 2 candidate lists. For example, 
it might be reassuring when users ﬁ  nd that their 
fresh observations appear repeatedly in similar 
independent studies. Users may also like to con-
duct a gene ontology breakdown on the biomark-
ers or f ind out which cancer related pathways the 
biomarkers in the candidate list belong to. Bar 
charts and histograms can also be used to display 
the distribution of molecular weight and isoelectric 
point values within the selected candidate list. 
These functionalities may act as individual mod-
ules where users may customize and combine 
commonly used sets of operations to run them in 
a series like a workﬂ  ow on their selected set of 
candidate list (Fig. 1E).
Discussion
To illustrate some of the functionalities of CLUB, 
we use it to analyze a public dataset from Bullinger 
et al. (Bullinger et al. 2004). The original data 
covers samples from 116 adults with Acute 
Myeloid Leukemia (AML, including 54 tissue 
samples derived from the bone marrow) which 
were analyzed by three separate platforms and 
classiﬁ  ed in terms of their clinical outcome (dead 
or alive) and genotype variation (normal or aber-
rant karyotype). We took the 20 bone marrow 
derived samples analyzed using the GEO accession 
GDS843 microarray platform, leaving out the 
sample with an intermediate phenotype. The 
expression level for each gene is compared with 
the levels of Corticotropin Releasing Hormone 
(CRH) expression. Only genes with greater than 
2-fold expression difference were included. We 
sought to identify potential prognostic biomarkers 
by choosing interaction network clusters that were 
only found in samples from dead patients and 
samples from living patients with aberrant karyo-
type. Differentially expressed genes that were 
highly represented in patients were selected to be 
analyzed. Henceforth, 3 gene lists were uploaded 
to CLUB: (i) the set of genes found in patients that 
were alive and have normal karyotype, (ii) the set 
of genes found in patients that were dead or have 
aberrant karyotype and (iii) the set of genes that 
were found differentially expressed in 7 or more 
patients. Using CLUB’s set operation (intersection) 
function, we ﬁ  lter for genes that were highly rep-
resented in the 2 groups of patients (Fig. 3A). 
Subsequently, with CLUB’s interacting function, 
gene-interaction networks were generated for the 
remaining genes that passed through the ﬁ  rst cri-
teria (Fig. 3B). In order to look for interacting 
networks that are speciﬁ  c to the group of patients 
with a poorer prognosis, we used CLUB’s set 
operation (“Set A but Not Set B”) to include all the 
saved genes found in the group that were dead or 
has an aberrant karyotype and excluded the genes 
that can be found in the group that were alive and 
have normal karyotype. Four potential prognostic 
biomarkers representing 2 interaction networks 
showed up from this series of procedures. The 
CCL21 (Small Inducible cytokine A21)—CCRL1 
(Chemokine Receptor Type 11) interaction are 
known to play a role in neoplastic metastasis while 
the GADD45G (Growth Arrest and DNA-Damage-
Inducible 45 Gamma) in the GADD45G- PTPRK 
(Protein Tyrosine Phosphatase Receptor type K) 
interaction is a known pro-apoptotic factor 
(Fig. 3C). These interaction network clusters rep-
resent candidate networks that are potentially 
speciﬁ  c to leukemia patients with well-advanced 
stage of cancer and therefore, a poorer prognosis 
for patients with these interaction networks. To 
ﬁ  nd out if these candidates were listed as potential 
biomarkers in Polanski and Anderson’s (Polanski 
and Anderson, 2006) list of 1261 candidate bio-
markers, we did an intersecting set operation with 
this list from CLUB. Two (GADD45G, CCL21) 
out of 4 candidates found in the 2 interaction net-
work clusters can also be found in Polanski and 
Anderson’s list. These results illustrate the useful-
ness of using analysis tools from CLUB to shortlist 
biomarkers that merit further clinical evaluations 
in AML patient prognosis. The network clusters 
may also act to correlate one candidate biomarker 
to another and may therefore assist researchers in 
the gene-enrichment and gene-ﬁ  ltering process.
As research is being conducted to understand 
why certain biomarkers work in the clinic, we hope 
to identify characteristics of clinically useful 70
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Figure 3. Screenshots from CLUB illustrating data ﬁ  ltering and analysis procedures to select potential prognostic markers from 
Bullinger et al.’s data.
(A) Filtering for highly represented diffentially expressed genes from the group of patients with poor prognosis. (B) Filtering for genes that 
correlate to one another via gene-gene interaction data. This procedure may provide biological insights to the gene list. (C) Interaction 
networks found only in the group of patients associated with poor prognosis.
biomarkers and eventually come up with a scoring 
system that ranks their likelihood of becoming a 
successful candidate. In future, CLUB may also 
include genetic, glycomic, lipidomic, metabolomic 
and other expression based biomarkers for analy-
sis. We also intend to design CLUB to make it more 
useful and relevant for clinicians. Researchers and 
clinicians with interests in the ﬁ  eld are invited to 
submit relevant candidate cancer biomarkers and/
or suggest improvements to the database. CLUB 
is available at http://club.bii.a-star.edu.sg/.
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